Download Files:
CID 2745687
$100 – $950
Products Details
Product Description
– CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM[1].
Web ID
– HY-107537
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C17H19F2N5O2S
References
– [1]Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8.|[2]Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95.|[3]Mi-Jeong Kim, et al. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35. Biomol Ther (Seoul). 2019 Jun 13;28(1):92-97.
CAS Number
– 264233-05-8
Molecular Weight
– 395.43
Compound Purity
– 98.07
SMILES
– O=C(C1=C(/C=N/NC(NC(C)(C)C)=S)N(C2=CC=C(C=C2F)F)N=C1)OC
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Cardiovascular Disease
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– GPR35
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
